New York State Common Retirement Fund Adverum Biotechnologies, Inc. Transaction History

New York State Common Retirement Fund

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.81 - $1.34 $42,039 - $69,546	-51,900 Reduced 98.62%	728 $1,000
Q4 2021 Feb 02, 2022	SELL	$1.74 - $2.4 $241 - $333	-139 Reduced 0.26%	52,628 $93,000
Q3 2021 Nov 02, 2021	BUY	$2.08 - $3.6 $316 - $547	152 Added 0.29%	52,767 $115,000
Q2 2021 Aug 02, 2021	SELL	$3.36 - $10.56 $87,645 - $275,457	-26,085 Reduced 33.14%	52,615 $184,000
Q4 2020 Feb 08, 2021	BUY	$9.84 - $14.26 $115,128 - $166,842	11,700 Added 17.46%	78,700 $853,000
Q2 2020 Aug 07, 2020	BUY	$8.53 - $25.64 $135,627 - $407,676	15,900 Added 31.12%	67,000 $1.4 Million
Q1 2020 May 06, 2020	BUY	$7.98 - $16.32 $65,436 - $133,824	8,200 Added 19.11%	51,100 $499,000
Q4 2019 Feb 05, 2020	SELL	$5.12 - $12.22 $58,880 - $140,530	-11,500 Reduced 21.14%	42,900 $494,000
Q2 2019 Aug 09, 2019	BUY	$5.1 - $11.89 $54,059 - $126,034	10,600 Added 24.2%	54,400 $647,000
Q2 2018 Aug 10, 2018	BUY	$5.3 - $6.9 $232,140 - $302,220	43,800 New	43,800 $232,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.